<DOC> 
<DOCNO>1090425_business_story_10873720.utf8</DOCNO> 
<TEXT> 
         
The Telegraph - Calcutta (Kolkata) | Business | Ranbaxy suffers Rs 761cr loss
                                                                                                               Ranbaxy suffers Rs 761cr loss
          OUR CORRESPONDENT                              
	New Delhi, April 24: Ranbaxy Laboratories has suffered a consolidated loss of Rs 761 crore for the first quarter ended March 31, 2009 against a profit of Rs 85.8 crore in the same quarter last year.        
	Sales dipped 4 per cent to Rs 1,558.4 crore compared with Rs 1,623.1 crore in the same period last year.        
	In the first quarter, the companys sales in North America declined 7 per cent to Rs 404 crore compared with Rs 435.1 crore in the same quarter last year.        
	This quarter has been challenging for the global economy and also the pharmaceutical industry with depreciation in several currencies and a downturn in demand and liquidity affecting performance, across sectors, Ranbaxy CEO and MD Malvinder Mohan Singh said.        
	Cipla net up        
	Ciplas net profit for the fourth quarter ended March 31 has increased 40.94 per cent to Rs 252.92 crore from Rs 179.45 crore in the same quarter last year.         
	Total operating income rose to Rs 1,366.74 crore from Rs 1,122.10 crore in the year-ago period.        
	Delhi High Court today allowed Cipla to manufacture and sell the generic version of patented lung cancer drug Erlotinib of Swiss pharma firm Hoffman La Roche.         
	Wockhardt loss        
	Mark-to-market losses of Rs 581-crore have resulted in Wockhardt suffering a loss of Rs 139 crore in 2008 against a profit of Rs 385.8 crore in the previous fiscal.         
	The mark-to-market losses were due to the steep devaluation of the rupee.                                                                                                                                                                 
</TEXT> 
</DOC>